TheraRadar
Clinical-Stage Companies / Ardea

Ardea

Pre-Approval PRO BETA
⚫

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 8/14/2017

35
Total Trials
7
Phase 3
7
Phase 2
0
Recruiting
221
Score

Pipeline by Phase

Phase 3
7
Phase 2
7
Phase 1
20

Therapeutic Focus

Gout Healthy Hyperuricemia Tophaceous Gout HIV Infections

Clinical Trials (35)

NCT01808144 Phase 3 COMPLETED

Lesinurad and Febuxostat Combination Extension Study in Gout

Started: 3/1/2013

NCT01808131 Phase 3 COMPLETED

Lesinurad and Allopurinol Combination Extension Study in Gout

Started: 2/1/2013

NCT01510158 Phase 3 COMPLETED

Combining Lesinurad With Allopurinol in Inadequate Responders

Started: 1/1/2012

NCT01650246 Phase 3 COMPLETED

Open-Label Lesinurad Monotherapy Extension Study in Gout

Started: 8/1/2012

NCT01493531 Phase 3 COMPLETED

Combining Lesinurad With Allopurinol in Inadequate Responders

Started: 12/1/2011

NCT01510769 Phase 3 COMPLETED

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

Started: 1/1/2012

NCT01508702 Phase 3 COMPLETED

Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

Started: 1/1/2012

NCT02498652 Phase 2 COMPLETED

Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

Started: 7/28/2015

NCT02246673 Phase 2 COMPLETED

RDEA3170 and Febuxostat Combination Study in Gout Subjects

Started: 10/1/2014

NCT01001338 Phase 2 COMPLETED

Allopurinol Combination Study

Started: 10/1/2009

NCT01927198 Phase 2 COMPLETED

RDEA3170 Monotherapy in Subjects With Gout

Started: 8/1/2013

NCT00955981 Phase 2 COMPLETED

Gout Dose Response Study

Started: 7/1/2009

NCT00741442 Phase 2 COMPLETED

A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout

Started: 7/1/2008

NCT00617526 Phase 2 COMPLETED

Naïve HIV POC Monotherapy Trial

Started: 1/1/2008

NCT03272425 Phase 1 COMPLETED

Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

Started: 8/14/2017

NCT02448368 Phase 1 COMPLETED

RDEA3170 Tablet and Capsule Bioavailability Study

Started: 5/1/2015

NCT02279641 Phase 1 COMPLETED

RDEA3170 and Allopurinol Combination Study in Gout Subjects

Started: 11/1/2014

NCT02336594 Phase 1 COMPLETED

RDEA3170 Bioavailability Study

Started: 11/1/2014

NCT02888054 Phase 1 COMPLETED

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

Started: 8/30/2016

NCT02219516 Phase 1 COMPLETED

Mild, Moderate and Severe Renal Impairment Study

Started: 8/1/2014

NCT02581553 Phase 1 COMPLETED

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

Started: 10/1/2015

NCT02608710 Phase 1 COMPLETED

RDEA3170 PK/PD Study

Started: 11/1/2015

NCT02398448 Phase 1 COMPLETED

IVIVR Assessing PK Parameters Used to Establish Bioequivalence

Started: 4/1/2015

NCT02127775 Phase 1 COMPLETED

Lesinurad Tablet Bioequivalence

Started: 4/1/2014

NCT01986556 Phase 1 COMPLETED

Lesinurad Tablet Relative Bioavailability

Started: 11/1/2013

NCT01982201 Phase 1 COMPLETED

Antacid Interaction Study

Started: 11/1/2013

NCT02039700 Phase 1 COMPLETED

Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

Started: 1/1/2014

NCT02028689 Phase 1 COMPLETED

Metformin and Furosemide Drug-Drug Interaction Study

Started: 10/1/2013

NCT01883167 Phase 1 COMPLETED

RDEA3170 and Febuxostat Drug Interaction Study

Started: 6/1/2013

NCT01908257 Phase 1 COMPLETED

Lesinurad Interaction Study With Ranitidine

Started: 7/1/2013

NCT01872832 Phase 1 COMPLETED

Single and Multiple Dose Study in Japanese Subjects

Started: 6/1/2013

NCT01910506 Phase 1 COMPLETED

RDEA3170 AME Study

Started: 8/1/2013

NCT01884272 Phase 1 COMPLETED

NSAID Drug Interaction Study

Started: 6/1/2013

NCT01744379 Phase 1 COMPLETED

Single and Multiple Dose Study in Japanese

Started: 12/1/2012

NCT01391325 Phase 4 COMPLETED

Allopurinol Outcome Study

Started: 7/1/2011

Drug Candidates

lesinurad/allopurinol 200/300 FDC tablets lesinurad 200 mg allopurinol 300 mg RDEA3170,10 mg RDEA3170, 2.5 mg RDEA3170, 5 mg RDEA3170, 10 mg lesinurad febuxostat RDEA3170 2.5 mg
Activity Status: Inactive
Last Trial Started: 8/14/2017
Last Trial Ended: 10/4/2017
Trials (12 months): 0
Completed Trials: 35
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.